198 related articles for article (PubMed ID: 23423490)
1. Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis.
Fushida S; Kinoshita J; Kaji M; Hirono Y; Goda F; Yagi Y; Oyama K; Sudo Y; Watanabe Y; Fujimura T;
Cancer Chemother Pharmacol; 2013 May; 71(5):1265-72. PubMed ID: 23423490
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma.
Park SR; Kim HK; Kim CG; Choi IJ; Lee JS; Lee JH; Ryu KW; Kim YW; Bae JM; Kim NK
Br J Cancer; 2008 Apr; 98(8):1305-11. PubMed ID: 18362939
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination.
Fujiwara Y; Nishida T; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Yamamoto K; Moon JH; Mori M; Doki Y
Anticancer Res; 2010 Apr; 30(4):1335-9. PubMed ID: 20530449
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
[TBL] [Abstract][Full Text] [Related]
5. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age.
Zang DY; Yang DH; Lee HW; Hwang SW; Song HH; Jung JY; Kwon JH; Kim HJ; Kim JH; Park SR; Kim MJ; Jang KM; Park CK; Kim JH; Lee BH
Cancer Chemother Pharmacol; 2009 Feb; 63(3):509-16. PubMed ID: 18481067
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination.
Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
J Surg Oncol; 2012 Jan; 105(1):38-42. PubMed ID: 21882194
[TBL] [Abstract][Full Text] [Related]
8. Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Kobayashi D; Ishigami H; Kanda M; Tanaka C; Yamaguchi H; Kitayama J; Kodera Y
Oncology; 2020; 98(1):48-52. PubMed ID: 31487733
[TBL] [Abstract][Full Text] [Related]
9. [A multi-centric phase I/II study of intraperitoneal docetaxel combined with S-1 for patients with peritoneal dissemination of gastric cancer].
Fushida S; Fujimura T; Fukushima N; Nashimoto A; Kaji M; Hirono Y; Yamaguchi K; Tanemura H; Imano M; Tsujitani S; Kurita N; Watanabe Y; Kurita A; Goda F; Ohta T
Gan To Kagaku Ryoho; 2007 Nov; 34(12):1942-5. PubMed ID: 18219859
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.
Uemura N; Kikuchi S; Sato Y; Ohnuma H; Okamoto K; Miyamoto H; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Okuda T; Minami S; Takahashi M; Okamoto T; Takada K; Miyanisi K; Takayama T; Kato J
Cancer Chemother Pharmacol; 2017 Oct; 80(4):707-713. PubMed ID: 28849257
[TBL] [Abstract][Full Text] [Related]
11. Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer.
Kurokawa Y; Hamakawa T; Miyazaki Y; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Mori M; Doki Y
Anticancer Res; 2015 Apr; 35(4):2223-8. PubMed ID: 25862882
[TBL] [Abstract][Full Text] [Related]
12. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.
Zang DY; Yang DH; Kim MJ; Jang KM; Hwang SW; Yoo KS; Han T; Kim HY; Kim HJ; Kwon JH; Song HH; Park S; Jung JY; Kim HS; Kim JH
Cancer Chemother Pharmacol; 2009 Oct; 64(5):877-83. PubMed ID: 19190908
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer.
Kim YH; Seo HY; Jeen YT; Kim HK; Shim BY; Yang J
Cancer Chemother Pharmacol; 2009 Jan; 63(2):253-60. PubMed ID: 18493761
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer.
Hosokawa A; Ando T; Ogawa K; Ueda A; Yoshita H; Mihara H; Fujinami H; Kajiura S; Yabushita K; Horikawa N; Kobayashi Y; Yoshioka A; Origasa H; Sugiyama T
Am J Clin Oncol; 2018 Oct; 41(10):977-981. PubMed ID: 28930775
[TBL] [Abstract][Full Text] [Related]
15. A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer.
Sato Y; Sagawa T; Ohnuma H; Hirakawa M; Takahashi Y; Hamaguchi K; Fujikawa K; Nobuoka T; Okamoto K; Miyamoto H; Muguruma N; Takemasa I; Takayama T
Cancer Chemother Pharmacol; 2019 Jan; 83(1):161-167. PubMed ID: 30406285
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer.
Yamaguchi K; Shimamura T; Hyodo I; Koizumi W; Doi T; Narahara H; Komatsu Y; Kato T; Saitoh S; Akiya T; Munakata M; Miyata Y; Maeda Y; Takiuchi H; Nakano S; Esaki T; Kinjo F; Sakata Y
Br J Cancer; 2006 Jun; 94(12):1803-8. PubMed ID: 16773074
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601).
Nakayama N; Koizumi W; Sasaki T; Higuchi K; Tanabe S; Nishimura K; Katada C; Nakatani K; Takagi S; Saigenji K
Oncology; 2008; 75(1-2):1-7. PubMed ID: 18719348
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.
Cho H; Ryu MH; Kim KP; Ryoo BY; Park SR; Kim BS; Lee IS; Kim HS; Yoo MW; Yook JH; Oh ST; Kim BS; Kang YK
Gastric Cancer; 2017 Nov; 20(6):970-977. PubMed ID: 28303362
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
